Evidence map›Paper›PMID 34976203›Full record

ArticleTheranostics2022

HDAC6 inhibition reverses long-term doxorubicin-induced cognitive dysfunction by restoring microglia homeostasis and synaptic integrity.

Blake R McAlpin, Rajasekaran Mahalingam, Anand K Singh, Shruti Dharmaraj, Taylor T Chrisikos, Nabila Boukelmoune, Annemieke Kavelaars, Cobi J Heijnen

Open access · goldAbstract read
In one paragraph

Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. HDAC6 Inhibition Reduces Seeded Tau and α-Synuclein Pathologies in Primary Neuron Cultures and Wild-Type Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Blake R McAlpinLaboratories of Neuroimmunology, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rajasekaran MahalingamLaboratories of Neuroimmunology, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anand K SinghLaboratories of Neuroimmunology, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shruti DharmarajLaboratories of Neuroimmunology, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Taylor T ChrisikosDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nabila BoukelmouneLaboratories of Neuroimmunology, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Annemieke KavelaarsLaboratories of Neuroimmunology, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cobi J HeijnenLaboratories of Neuroimmunology, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Neuroimmune Mechanisms of Recovery from Comorbid Depression and Chronic PainR01NS073939 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DANTZER, ROBERT, HEIJNEN, COBI J · 2011 to 2020
$4.0M
A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicityR01CA230512 · NCI · SAINT LOUIS UNIVERSITY · PI SALVEMINI, DANIELA · 2018 to 2022
$2.8M
Mesenchymal Stem Cells to Repair ChemobrainR01CA208371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIJNEN, COBI J, SHEPHERD, ANDREW JOHN · 2016 to 2020
$2.4M
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and ChemobrainR01CA227064 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRACE, PETER M, SHEPHERD, ANDREW JOHN · 2018 to 2023
$2.2M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA208371NCI NIH HHS R01 CA227064NCI NIH HHS R01 CA230512NINDS NIH HHS R01 NS073939
6 · The paper itself

Abstract

Breast cancer is the most common female malignancy in both the developed and developing world. Doxorubicin is one of the most commonly used chemotherapies for breast cancer. Unfortunately, up to 60% of survivors report long-term chemotherapy-induced cognitive dysfunction (CICD) characterized by deficits in working memory, processing speed and executive function. Currently, no therapeutic standard for treating CICD exists. Here, we hypothesized that treatment with a blood-brain barrier permeable histone deacetylase 6 (HDAC6) inhibitor can successfully reverse long-term doxorubicin-induced cognitive dysfunction.

Indexed as

AnimalsCognitive DysfunctionDisks Large Homolog 4 ProteinDose-Response Relationship, DrugDoxorubicinFemaleHippocampusHistone Deacetylase 6HomeostasisMiceMice, Inbred C57BLMicrogliaMitochondriaPyridazinesSynapsesTranscription, GeneticACY1083Disks Large Homolog 4 ProteinDlg4 protein, mouseDoxorubicinHdac6 protein, mouseHistone Deacetylase 6Pyridazineschemobrainchemotherapy-induced cognitive dysfunctionHDAC6 inhibitionmicrogliasingle-nucleus RNA sequencing

Identifiers

PMID34976203
PMCPMC8692908
OpenAlexW4200586764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.